瑞舒伐他汀对急性心肌梗死介入术后炎性反应和血管内皮功能的影响  

Effect of Rosuvastatin on the function of vascular endothelial and inflammatory response in patients with acute myocardial infarction after intervention

作　　者：王景斌[1] 仝峰[1] 张颖[1] 杨琴[1] 

机构地区：[1]河南省焦作市第二人民医院心血管内科,454001

出　　处：《中国综合临床》2010年第8期815-817,共3页Clinical Medicine of China

摘　　要：目的 观察瑞舒伐他汀对急性心肌梗死（AMI）患者经皮冠状动脉介入治疗（PCI）后炎性因子和血管内皮功能的影响.方法 78例AMI患者均行冠状动脉造影及PCI治疗,术后分为对照组38例和瑞舒伐他汀组40例.2组患者均常规使用硝酸酯类、低分子肝素钙、阿司匹林、氯吡格雷.瑞舒伐他汀组在常规用药基础上加服瑞舒伐他汀10 mg/次,每日1次.2组均连续用药6个月.记录所有患者出院后6个月内心血管事件,检测血脂、炎症相关生物标志物和血管内皮功能.结果 出院后6个月内瑞舒伐他汀组心血管事件发生率（5.0%）显著低于对照组（18.4%）,差异有统计学意义（χ2=4.52,P〈0.05）;6个月后瑞舒伐他汀组甘油三酯（TG）、胆固醇（TC）、白细胞介素-6（IL-6）、超敏C-反应蛋白（hs-CRP）、内皮素-1（ET-1）及氧化低密度脂蛋白（ox-LDL）[（2.15±0.54）mmol/L;（4.16±0.28）mmol/L;（6.80±2.65）ng/L;（4.02±1.58）mg/L;（62.45±9.38）ng/L;381.65±39.73]比对照组（（2.47±0.59）mmolL;（5.29±0.31）mmol/L：（9.39±4.17）ng/L;（5.76±1.52）mg/L;（81.75±10.23）ng/L;485.91±42.68]显著降低（t值分别为2.423、16.910、3.291、4.952、8.691、11.173,P均〈0.01）;瑞舒伐他汀组血一氧化氮（62.17±17.69）μmoL/L比对照组（48.27±18.35）μmol/L显著升高（t=3.406,P〈0.01）.瑞舒伐他汀组未发现严重的不良反应.结论 瑞舒伐他汀可减轻AMI患者PCI术后炎性反应,改善血管内皮功能,且不良反应少.Objective To observe the effect of Rosuvastatin on the function of vascular endothelial and inflammatory response in patients with acute myocardial infarction （ AMI） after intervention. Methods Seventy-eight patients with AMI patients underwent coronary angiography and PCI treatment The patients were divided into the control group （38 patients） and the Rosuvastatin group （40 patients） after PCI treatment All patients were routinely used nitrates, low molecular weight heparin,aspirin,clopidogrel,the Rosuvastatin group were treated on the basis of conventional medication plus service Rosuvastatin 10 mg/time, once a day. Both groups were continuous medicated for 6 months. Cardiovascular events of all patients, the serum lipids, inflammation-related biomarkers and indicators of vascular endothelial function were followed up for 6 months after discharge. Results The cardiovascular events in the Rosuvastatin group （5. 0% ） was significantly lower than that of the control group （18.4%） after discharge within 6 months （χ2 = 4. 52, P 〈 0. 05）. After 6 months of discharge, the serum lipids, the serum IL-6, hs-CRP,plasma ET-1 and ox-LDL of Rosuvastatin group （（2. 16 ±0. 54）mmol/L,（4. 16 ±0. 28）mmol/L,（6. 80 ± 2. 65） ng/L, （4. 02 ± 1. 58） mg/L, （ 62. 45 ± 9. 38） ng/L and 381. 65 ± 39. 73, respectively） was significantly lower than those of the control group （（2.47 ±0. 59） mmol/L, （5. 29 ±0. 31 ）mmol/L, （9. 39 ±4. 17） ng/L, （5. 76 ± 1. 52）ng/L, （81. 75 ± 10. 23） ng/L and 485. 91 ±42. 68,respectively） （t =2. 423,16. 910,3. 291,4. 952,8. 691 and 11. 173 , respectively , P 〈0. 01 ）. The serum NO of Rosuvastatin group （ （ 62. 17 ± 17. 69 ） μmol/L） was significantly higher than than that of the control group （ （48. 27 ±18. 35 ） μmol/L） （t = 3.406, P 〈 0.01 ） . The serious adverse events were not observed in the Rosuvastatin group. Conclusions Rosuvastatin reduces inflammatory reaction after PCI in patients with AM

关 键 词：急性心肌梗死 瑞舒伐他汀 经皮冠状动脉介入治疗 炎性因子 内皮功能 

分 类 号：R542[医药卫生—心血管疾病]